by François Briand | Jun 10, 2022 | 2022
Physiogenex will be presenting the effects of clinical benchmarks in its innovative obese NASH hamster model on June the 13th, 2022 at the Keystone Symposia “Tissue Fibrosis and Repair”, to be held in Keystone, Colorado, USA. Meet Dr François Briand, our...
by François Briand | Jun 2, 2022 | 2022
Physiogenex will be presenting a new DIO-NASH mouse study at the 82nd Scientific Sessions of the American Diabetes Association in New Orleans, LA, USA, June 3-7, 2022. The oral presentation (#272-OR), entitled “Weight Loss with Time-Restricted Feeding or...
by François Briand | May 23, 2022 | 2022
Physiogenex will be presenting the cardiometabolic benefits of clinical benchmarks in its innovative obese NASH hamster model on May 26-27th, 2022 at the Global NASH conference in London, UK. Meet Dr François Briand, our Director of Research and Development at each...
by François Briand | May 13, 2022 | 2022
Physiogenex will be presenting its two obese/type 2 diabetic rat models of nephropathy at the 59th ERA congress in Paris France May 19-22th, 2022. The first abstract is entitled “THE LUND METS RAT, AN OBESE TYPE 2 DIABETIC PRECLINICAL MODEL, DEVELOPS...
by François Briand | May 3, 2022 | 2022
Physiogenex will be presenting the effects of SARS-CoV-2 infection on dyslipidemia and NASH in its obese hamster model at Vascular Discovery 2022, to be held in Seattle, WA, USA on May12th-14th. The oral abstract#112 entitled “Sars-CoV-2 Infection Promotes...
by François Briand | Apr 19, 2022 | 2022
Physiogenex will be presenting the cardiometabolic benefits of the GLP-1 receptor agonist semaglutide in its innovative obese NASH hamster model on April 28th-30th, 2022 at the International Conference on Fatty Liver in Vienna, Austria. Meet Dr François Briand, our...
